组蛋白去乙酰化酶在抑郁障碍中的研究进展
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Research progress of histone deacetylase in depressive disorder
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    抑郁障碍由于病因不明及药物治疗的有限性,导致其在医疗、社会及经济上成为一个棘 手问题。表观遗传调控在神经系统发育及精神疾病中起着重要作用,近年来许多动物应激模型证实在 大脑特定区域存在某些组蛋白去乙酰化酶表达异常,从而产生抑郁样行为。组蛋白去乙酰化酶抑制剂 作为表观遗传调控的药物能够调节基因转录,被证实能产生一定的抗抑郁效应。本文就组蛋白去乙酰 化酶及其抑制剂在抑郁障碍中的研究进行综述,旨在为治疗抑郁障碍提供更广阔的选择。

    Abstract:

    Depressive disorder is a serious medical, public and economic problem because of its unknown etiology and limitation of drug treatment. Epigenetic regulation plays an important role both in neural development and psychiatric disorders. In recent years many stress animal models identified abnormal expression of some histone deacetylases in particular brain regions which lead to depression-like behaviors. Histone deacetylase inhibitors, as a kind of epigenetic regulatory drugs, can regulate gene transcription, thus have antidepressant effect. This paper reviews the research progress of histone deacetylase and its inhibitors in depressive disorder and provides a wider range of options for the treatment of depressive disorder.

    参考文献
    相似文献
    引证文献
引用本文

任少宇 刘嘉颖.组蛋白去乙酰化酶在抑郁障碍中的研究进展[J].神经疾病与精神卫生,2020,20(12):
DOI :10.3969/j. issn.1009-6574.2020.12.008.

复制
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-02-04